S M Opal

Summary

Affiliation: Brown University
Country: USA

Publications

  1. ncbi Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals
    S M Opal
    Division of Infectious Diseases, University School of Medicine, Providence, Rhode Island, USA
    J Infect Dis 178:1205-8. 1998
  2. ncbi Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock
    S M Opal
    Infectious Disease Division, Brown University School of Medicine and Memorial Hospital of Rhode Island, Providence, Rhode Island 02860, USA
    J Infect Dis 180:1584-9. 1999
  3. ncbi Recombinant human interleukin-11 has anti-inflammatory actions yet does not exacerbate systemic Listeria infection
    S M Opal
    Division of Infectious Diseases, Brown University School of Medicine, Memorial Hospital of Rhode Island, Pawtucket, RI 02860, USA
    J Infect Dis 181:754-6. 2000
  4. ncbi The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis
    S M Opal
    Brown University School of Medicine, Providence, RI, USA
    Crit Care Med 29:13-7. 2001
  5. ncbi Evaluation of the safety of recombinant P-selectin glycoprotein ligand-immunoglobulin G fusion protein in experimental models of localized and systemic infection
    S M Opal
    Infectious Disease Division, Brown University School of Medicine, Providence, Rhode Island, USA
    Shock 15:285-90. 2001
  6. ncbi Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis
    A S Cross
    Division of Infectious Diseases, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Infect Dis 183:1079-86. 2001
  7. ncbi Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions
    S M Opal
    Infectious Disease Division, Brown University School of Medicine, Providence, Rhode Island, USA
    Drugs 55:497-508. 1998
  8. ncbi Clinical impact of novel anticoagulation strategies in sepsis
    S M Opal
    Brown University School of Medicine, and Director, Infectious Disease Division, Memorial Hospital of Rhode Island, Pawtucket 02860, Rhode Island, USA
    Curr Opin Crit Care 7:347-53. 2001
  9. ncbi Anti-inflammatory cytokines
    S M Opal
    Infectious Disease Division, Brown University School of Medicine, Providence, RI, USA
    Chest 117:1162-72. 2000
  10. ncbi Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers
    M A Neill
    Brown University Program in Medicine, Providence, Rhode Island
    Ann Intern Med 114:195-9. 1991

Collaborators

Detail Information

Publications10

  1. ncbi Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals
    S M Opal
    Division of Infectious Diseases, University School of Medicine, Providence, Rhode Island, USA
    J Infect Dis 178:1205-8. 1998
    ..05). These results indicate that rhIL-11 supports mucous membrane integrity of the alimentary tract and decreases the systemic inflammatory response to experimental gram-negative infection in immunocompromised animals...
  2. ncbi Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock
    S M Opal
    Infectious Disease Division, Brown University School of Medicine and Memorial Hospital of Rhode Island, Providence, Rhode Island 02860, USA
    J Infect Dis 180:1584-9. 1999
    ..05) in nonsurvivors than survivors over the 28-day study period. No correlation was found between endotoxin and LBP levels. The quantitative level of both endotoxin and LBP may have prognostic significance in patients with severe sepsis...
  3. ncbi Recombinant human interleukin-11 has anti-inflammatory actions yet does not exacerbate systemic Listeria infection
    S M Opal
    Division of Infectious Diseases, Brown University School of Medicine, Memorial Hospital of Rhode Island, Pawtucket, RI 02860, USA
    J Infect Dis 181:754-6. 2000
    ..The results indicate that IL-11 down-regulates cytokine production but does not exacerbate systemic infection in the murine Listeria infection model...
  4. ncbi The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis
    S M Opal
    Brown University School of Medicine, Providence, RI, USA
    Crit Care Med 29:13-7. 2001
    ..To study recombinant human tissue factor pathway inhibitor (rhTFPI) in a superantigen-induced shock model and in a cecal ligation and puncture (CLP) model of peritonitis in mice...
  5. ncbi Evaluation of the safety of recombinant P-selectin glycoprotein ligand-immunoglobulin G fusion protein in experimental models of localized and systemic infection
    S M Opal
    Infectious Disease Division, Brown University School of Medicine, Providence, Rhode Island, USA
    Shock 15:285-90. 2001
    ..The results indicate that rPSGL-Ig did not exacerbate infection in these experimental sepsis models...
  6. ncbi Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis
    A S Cross
    Division of Infectious Diseases, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Infect Dis 183:1079-86. 2001
    ..Active immunization with this vaccine merits further investigation...
  7. ncbi Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions
    S M Opal
    Infectious Disease Division, Brown University School of Medicine, Providence, Rhode Island, USA
    Drugs 55:497-508. 1998
    ..It will require focused efforts by basic scientists, continued support by industry and enlightened study designs by clinical investigators to successfully develop antiendotoxin in therapies for use in septic patients in the future...
  8. ncbi Clinical impact of novel anticoagulation strategies in sepsis
    S M Opal
    Brown University School of Medicine, and Director, Infectious Disease Division, Memorial Hospital of Rhode Island, Pawtucket 02860, Rhode Island, USA
    Curr Opin Crit Care 7:347-53. 2001
    ..Anticoagulants such as recombinant human activated protein C and related agents may become the mainstay of adjuvant therapies for severe sepsis in the near future...
  9. ncbi Anti-inflammatory cytokines
    S M Opal
    Infectious Disease Division, Brown University School of Medicine, Providence, RI, USA
    Chest 117:1162-72. 2000
    ..The nature of anti-inflammatory cytokines and soluble cytokine receptors is the focus of this review. The current and future therapeutic uses of these anti-inflammatory cytokines are also reviewed...
  10. ncbi Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers
    M A Neill
    Brown University Program in Medicine, Providence, Rhode Island
    Ann Intern Med 114:195-9. 1991
    ..To determine the efficacy of ciprofloxacin therapy in eradicating convalescent fecal excretion of salmonellae after acute salmonellosis...